MI
Mirum Pharmaceuticals, Inc.
MIRM · NASDAQ
$93.90 -3.76% (-$3.67)
1M -5.94%
Market Cap $5.73B
P/E Ratio -
Div. Yield -
ROE 410.20%
Bulios Fair Price
$70.98
24.4% downside
Current Price
$93.9
Undervalued Fair Value Overvalued
According to Bulios Fair Price, MIRM is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
3/9Valuation
0 /100
Expensive P/S 9.26x
P/E N/A
EV/EBITDA N/A
Growth
100 /100
Growing Rev. growth 89.13%
Book val. growth 30.36%
EPS growth N/A
Profitability
20 /100
Weak Gross margin 81.70%
Net margin 139.18%
Op. margin 17.42%
Quality
7 /100
Poor ROIC 13.14%
ROE 410.20%
ROA 82.32%
Debt
43 /100
Moderate Current ratio 2.86x
Int. coverage -59.74x
Debt/Equity N/A
Stability
35 /100
Moderate Beta 0.49x
Rev. volatility 44.71%
EPS volatility 38.21%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about MIRM
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Christopher Peetz
Employees
433
Headquarters
Foster City
Upcoming events
03 NOV
Earnings
Upcoming earnings report